Showing 1171-1180 of 1604 results for "".
- It's Official: Venus Concept Completes Merger with Restoration Roboticshttps://practicaldermatology.com/news/its-official-venus-concept-completes-merger-with-restoration-robotics/2460207/Venus Concept Inc. has completed its previously announced merger with Restoration Robotic, Inc., effective November 7, 2019. Following the completion of the merger, Venus Concept completed a $28 million equity financing by EW Healthcare Partners, HealthQuest Capital, SEDCO Capital
- ASDSA Honors 2019 Patient Safety Heroeshttps://practicaldermatology.com/news/asdsa-honors-2019-patient-safety-heroes/2460203/The American Society for Dermatologic Surgery Association (ASDSA) honored the recipients of its annual Patient Safety Hero awards at the recent ASDS Annual Meeting in Chicago, Illinois. The ASDSA State Legislative Patient Safety Hero Award is presented to a state legislative member who
- Going for the Gold: Sebacia Microparticles Help Direct Lasers to the Source of Acnehttps://practicaldermatology.com/news/going-for-the-gold-sebacia-microparticles-help-direct-lasers-to-the-source-of-acne/2460199/Sebacia microparticles may be acne’s latest and greatest nemesis. New research presented the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in Chicago shows that the technology helps to safely and effectively clear acne wh
- Foamix Update: Nine Trials in Five Postershttps://practicaldermatology.com/news/foamix-update-nine-trials-in-five-posters/2460192/Results from nine clinical trials of Foamix Pharmaceutical investigational products will be presented in five posters at the 39th Annual Fall Clinical Dermatology Conferencein Las Vegas. Findings relate FMX101 for the treatment of moderate-to-severe acne and FMX103 for the treatment of moderate-t
- Dermira Shares Positive Data From Phase 2b Study of Lebrikizumab for Atopic Dermatitis at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/dermira-shares-positive-data-from-phase-2b-study-of-lebrikizumab-for-atopic-dermatitis-at-fall-clinical-dermatology-conference/2460190/Primary results from Dermira, Inc.'s Phase 2b dose-ranging study of lebrikizumab were presented during the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderat
- Lilly: New Data for Treatment of Complex Dermatological Conditions at EADV, Maui Derm NP+PAhttps://practicaldermatology.com/news/lilly-new-data-for-treatment-of-complex-dermatological-conditions-at-eadv-maui-derm-nppa/2460188/New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress in Madrid. The company says the research h
- Verrica Pharmaceuticals: Positive Data for VP-102 for Molluscum Contagiosum, Wartshttps://practicaldermatology.com/news/verrica-pharmaceuticals-positive-data-for-vp-102-for-molluscum-contagiosum-warts/2460187/Positive data for VP-102 (cantharidin 0.7% Topical Solution) from Verrica Pharmaceuticals, Inc. are being presented in poster form at the Annual Fall Clinical Dermatology Conference in Las Vegas. Company’s lead product candidate is being developed for the treatment of molluscum c
- Obagi Program at ASDS to Focus on Inclusionhttps://practicaldermatology.com/news/obagi-program-at-asds-to-focus-on-inclusion/2460183/Obagi and actor, producer and activist, Priyanka Chopra Jonas, will lead a panel of top dermatologists in a discussion about the importance of diversity and inclusion in medical aesthetics during the annual meeting of the American Society for Dermatologic Surgery (ASDS) in Chicago next week. 
- Allergan Shareholders Approve Proposed Acquisition by AbbViehttps://practicaldermatology.com/news/allergan-shareholders-approve-proposed-acquisition-by-abbvie/2460181/Allergan’s shareholders approved the previously announced proposed acquisition of Allergan by AbbVie Inc. More than 99 percent of the votes cast at both a special court-ordered meeting of shareholders and at an extraordinary general meeting of shareholders were in favor of the tra
- Positive Phase 2 Results Seen With Galderma’s Proprietary Liquid Toxin for Frown Lineshttps://practicaldermatology.com/news/positive-phase-2-results-seen-with-galdermas-proprietary-liquid-toxin-for-frown-lines-2/2460170/Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines, according to Phase 2 study results. Pivotal Phase 3 trials for Galderma's liquid formulation of botulinum toxin type A for the treatment of glabellar lines are expecte